HiSight Medical, a cutting-edge medical device enterprise established in September 2020, is dedicated to the prevention and treatment of blinding eye diseases. The company has developed three core technology platforms and has recently finalized a fresh round of financing, spearheaded by Huaxing Kangping. These funds will be earmarked for propelling the commercialization of its flagship MIGS (Minimally Invasive Glaucoma Surgery) products, as well as accelerating the research and development of a retinal fundus pathway brain-computer interface visual reconstruction system. This strategic move aims to foster parallel growth in the commercialization of established products and the independent innovation of groundbreaking technologies.

As a trailblazer in China's MIGS sector, HiSight Medical has independently created the MicroCOGO® trabecular meshwork micro-stent drainage system, which currently holds the distinction of being the smallest Class III implant in the country. In early 2024, this product made history by becoming the first in the domestic MIGS field to qualify for the National Special Review Procedure for Innovative Medical Devices. With numerous clinical benefits, it is poised to make a significant impact on the lives of millions of glaucoma patients once commercialization gains momentum.

Simultaneously, the company is proactively exploring a retinal fundus pathway brain-computer interface visual reconstruction system, addressing the global ophthalmic challenge of blindness caused by dry age-related macular degeneration. Technical verification processes are currently underway in a systematic and orderly fashion.

Founder Dr. Zhao Peng emphasized that the company will harness its technological prowess to drive progress on both fronts, with the ambition of becoming a globally recognized leader in ophthalmic medical device innovation. Huaxing Kangping, expressing confidence in HiSight Medical's technological acumen, industrialization capabilities, and innovative spirit, pledged to utilize its own resource advantages to bolster the company's growth and jointly advance the implementation of domestic ophthalmic innovation technologies, fostering high-quality development in the domestic high-end ophthalmic medical device industry.